Latest News Releases From The Newsroom
SEC Charges Former Pfizer Statistician with Insider Trading Ahead of COVID-19 Announcement
June 29th, 2023
Employee and friend traded ahead of Pfizer’s “game-changer” announcement on the success of its Paxlovid trial FOR IMMEDIATE RELEASE 2022-123 Washington D.C. / CRWE PRESS RELEASE / June 29, 2023 - The Securities and Exch. Read more
BREAKING: BioXcel's Regulatory Inquiry Status Sends Shares Tumbling
June 29th, 2023
Shares of BioXcel Therapeutics, Inc.? (Nasdaq: BTAI) plunged by over 50% in premarket trading following the company's disclosure of a regulatory inquiry into the development of BXCL501, as revealed in a regulatory filing with the SEC. Despite this. Read more
Joby's Pre-Market Surge, Nano Dimension's Milestone Quarter: What You Need to Know
June 29th, 2023
Shares of Joby Aviation, Inc. (NYSE: JOBY) experienced a significant surge of over 10% in pre-market trading following the announcement of an equity investment by SK Telecom Co., Ltd.? (NYSE: SKM), a prominent telecommunications company in South Kore. Read more
Earnings Beat: BlackBerry, Greenbrier, and Acuity Brands in the Spotlight
June 29th, 2023
Shares of BlackBerry Limited (NYSE: BB) experienced a significant surge of over 10% in pre-market trading following the release of better-than-expected financial results. The company delivered a surprise profit for the first quarter of fiscal 2024. Read more
Bullishness: ZI, GPC, SQSP, DE, VVI, WIX, ARRY, GDDY - Top Buy Ratings
June 29th, 2023
ZoomInfo Technologies Inc. (Nasdaq: ZI), a leading provider of go-to-market intelligence solutions, received coverage initiation from Needham with a Buy rating and a price target of $35. Despite closing at $25.61 on Wednesday, the stated pri. Read more
FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes
June 28th, 2023
Silver Spring, MD / CRWE PRESS RELEASE / June 28, 2023 - Today, the U.S. Food and Drug Administration approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treat. Read more
Gilead Boosts Stake In AlloVir; Significant Contracts for RTX and Textron
June 28th, 2023
Biopharmaceutical leader Gilead Sciences, Inc. (Nasdaq: GILD) has disclosed its acquisition of 2,930,870 shares of AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, in a regulatory filing FORM 4 with the SEC. The shares were a. Read more
Micron Q3 Beats Estimates, Concentrix Lowers FY23 Revenue Forecast
June 28th, 2023
Shares of Micron Technology, Inc. (Nasdaq: MU) surged in after-hours trading following the release of its better-than-expected financial results. In the third quarter of fiscal 2023, Micron reported a loss of $1.43 per share and revenue of $3.752 . Read more
Breaking: General Mills and Roivant Sciences - Earnings Reaction
June 28th, 2023
General Mills, Inc. (NYSE: GIS) released its fourth-quarter fiscal 2023 earnings report, surpassing the consensus estimates for earnings per share (EPS). The company reported an EPS of $1.12, exceeding the consensus of $1.07. However, its sa. Read more
Pfizer, OPKO Health: FDA OKs GHD Treatment; Eton Pharma Faces Regulatory Setbacks
June 28th, 2023
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (Nasdaq: OPK) said that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly treatment for pediatric patients with growth hormone deficiency (G. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login